

Sex-, and neurodegeneration-dependent effect modification in the association between thyroid function and cognitive impairment in non-depressed, non-demented elderly

Asma Hallab^{a,b,c,#}, for the Alzheimer's Disease Neuroimaging Initiative*

Affiliations

a- Biologie Intégrative et Physiologie – Parcours Neurosciences Cellulaires. Faculté des Sciences et Ingénierie, Sorbonne Université, Paris, France.

b- Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin. Institute of Public Health. Berlin, Germany.

c- Pathologies du Sommeil. Faculté de Médecine Pitié-Salpêtrière, Sorbonne Université, Paris, France.

#Corresponding author

Dr. med. Dr. Asma Hallab

Charité Universitätsmedizin – Berlin

Chariteplatz 1, 10117 Berlin, Germany.

asma.hallab@charite.de

<https://orcid.org/0000-0002-3901-7980>

Abstract

Introduction: Understanding the particularities of thyroid-cognition interactions in the elderly is crucial in assessing the risks and evaluating therapeutic options.

Methods: Cross-sectional analyses where participants from Alzheimer's Disease Neuroimaging Initiative (ADNI) with mild cognitive impairment (MCI) and healthy controls (HC), with complete neurocognitive tests, thyroid stimulating hormone (TSH) <10 $\mu\text{IU/mL}$, and geriatric depression scale (GDS) <5 were eligible. Linear and logistic regression models, including testing for non-linearity, were performed. Sex and neurodegeneration-related stratifications were explored.

Results: Of the total 1845 participants, with a median age of 73 (IQR: 68, 78); 887 (48%) were females, and 1056 (57%) had MCI. The median TSH level was 1.70 $\mu\text{IU/mL}$ (IQR: 1.15, 2.40). There was a significant association between TSH and cognition only in males (adj. β_{Males} : -0.40; 95% CI: -0.74, -0.07; p -value: 0.019). The odds of being diagnosed with MCI at baseline decreased with higher TSH levels in the total study population (adj. OR_{Total} : 0.87; 95% CI: 0.79, 0.95; p -value: 0.002), and in males (adj. OR_{Males} : 0.80; 95% CI: 0.70, 0.92; p -value: 0.001). The median TSH value was a significant cutoff in this association.

Conclusions: The association between thyroid function and cognitive decline in the elderly is subject to a sex-driven effect modification and depends on a cutoff value.

Plain English summary:

The thyroid–brain association starts at very early stages of the nervous system development and plays a central role in cognition. During the aging process, the thyroid maintains an important role in modulating mental health well-being and associated risks. Older persons are at higher risk of hypothyroidism (lower functioning of thyroid hormone), which is a risk factor for reversible cognitive impairment and dementia. The current study explored the association between thyroid stimulating hormone, a central biomarker of thyroid function, and cognitive function in the elderly. People with dementia, depression, and overt hypothyroidism were excluded to better assess the risks beyond those well-established risk factors. Using different advanced statistical methods, a significant association between thyroid function and cognitive impairment was observed only in males but not females. The association was particularly relevant in older males with lower TSH levels under the median TSH value. Sex-related mechanisms and the reversibility of the association after appropriate intervention are still unclear. It is therefore important to explore thyroid-brain interactions in males and females separately and use methods testing for non-linear associations. The study design based on a cross-sectional analysis of baseline data does not imply causation and randomized longitudinal studies are needed.

Highlights:

- ADAS₁₃ total score was negatively correlated with TSH levels in a statistically significant manner only in males.
- Higher TSH levels predicted significantly lower ADAS₁₃ scores only in males.
- Lower TSH levels were significantly associated with higher odds of mild cognitive impairment only in males.
- The median TSH value was a significant cutoff point in the association between thyroid function and mild cognitive impairment.

Keywords: Thyroid, Aging, Cognition, Sex difference, Hormone, Neuroendocrinology


Graphical abstract

Background: Thyroid-brain interaction begins very early during the neurodevelopmental stages and persists over a lifetime. Understanding the particularities of the thyroid-brain interaction in the elderly is crucial in assessing the risks and evaluating therapeutic options. The study's aim was to explore the associations between Thyroid Stimulating Hormone (TSH) and cognition in non-depressed non-demented elderly.

Methods: Cross-sectional analysis of ADNI data. Linear and logistic regression models, including testing for non-linearity, were performed. Sex- and neurodegeneration-related stratifications were explored. Models were adjusted for age, \pm sex, \pm main diagnosis (controls vs. Mild Cognitive Impairment (MCI)), educational level, racial profile, APOE ϵ 4, and Body-Mass Index (BMI).


Females

Thyroid function was neither associated with overall cognition nor with the odds of MCI in females.



Males

Lower TSH values were significantly associated with worse cognitive function and higher odds of MCI in males.



Conclusions: The association between thyroid function and overall cognition is subject to sex-driven effect modification and depends on a cutoff value.

1. Introduction

Cognitive impairment is a serious public health concern, affecting millions worldwide and severely impacting their quality of life and independence. It is estimated that 152.8 million persons worldwide will experience some form of dementia by 2050. (1) Understanding related risk factors is crucial for preventive and interventional strategies. Various physiological systems are involved in cerebral functioning and cognition, and the thyroid plays a pivotal role in this body-brain association. (2) Thyroid-brain interactions begin very early during the neurodevelopmental stages and persist over a lifetime. (3, 4) During adulthood and the aging process, thyroid hormones maintain a central role in modulating the risk of mental health, being significantly associated, in a sex-dependent manner, (5) with the onset and complications of affective and psychotic disorders. (6-11) Thus, the impact of thyroid hormones on cognitive functions, particularly the association between dysthyroidism, whether hypothyroidism (low functioning) or hyperthyroidism (high functioning) on one side and cognitive decline during the aging process on the other side, is an emerging research field with multiple edges and of high complexity. Studies in adults and the elderly reported controversial outcomes, depending on the underlying demographical particularities and the assessed physiological risk factors. (12-16) Owing to a physiologically increased risk of subclinical hypothyroidism in the elderly, (17, 18) concomitantly with an increased risk of neurodegeneration and cognitive decline, understanding the interaction between both conditions is crucial to minimize the risks. Furthermore, women are more prone to thyroid disorders (19) and exhibit different patterns of cognitive decline than men. (20, 21) It is therefore unclear how significant sex-related biological factors might interfere with the thyroid-cognition association.

The general aim of this study was to explore the associations between thyroid function and cognition in non-depressed non-demented elderly and identify the major effect modifiers. The first aim was to explore whether there is a significant association between thyroid function and overall cognition in the elderly and whether this association is affected by sex or neurodegenerative status. The second aim was to evaluate whether thyroid function is associated with the odds of being diagnosed with mild cognitive impairment (MCI) at baseline.

2. Methods

2.1. Study population

Alzheimer's Disease Neuroimaging Initiative (ADNI) study participants with complete baseline data on demographic characteristics, thyroid function, depression assessment, and overall cognition were included. ADNI, an NIH-funded project (ADNI; National Institutes of Health Grant U19 AG024904 - more in acknowledgments), is a multicenter observational cohort aiming to study the cognitive decline in the elderly and better understand Alzheimer's disease risks. Dr. Michael Weiner is ADNI's principal investigator. The first cohort (ADNI 1) started in 2004, and several medical centers around the United States and Canada were involved in recruiting study participants. Following ADNI-1, ADNI-Go, -2, -3, and -4 (ongoing) included more study participants and applied more sophisticated neuropsychiatric and neuroimaging methods. Healthy controls (HC), elderly with MCI, and those with dementia participated in these cohorts. Participants completed written consents for taking part in ADNI. The study was performed according to the Declaration of Helsinki, and ethical approvals were obtained from the local IRBs corresponding to each study center. Study

protocols and information on ethical approvals, consent, detailed methods, funding, and data can be found at <https://adni.loni.usc.edu>.

2.2. Thyroid function

Fasting blood samples were collected at baseline. The time between blood collection to freezing did not exceed 120 min. Central thyroid function was explored and thyroid stimulating hormone (TSH) levels, reported in $\mu\text{IU/mL}$ (= mIU/L), were used for this analysis. In the case of repeated measurements, only the first value was retained since the possibility that the study participant received a hormonal supplementation or intervention between the two assessments cannot be precisely verified or excluded. Very low TSH levels (reported as “<0.01”) were converted to 0.01 for the analysis (in three cases). Only participants with $\text{TSH} < 10 \mu\text{IU/mL}$ were included, excluding cases with eventual overt hypothyroidism.

Thyroid function was explored in the main analysis based on a continuous variable of TSH ($\mu\text{IU/mL}$). TSH values 0.4 and 4.5 $\mu\text{IU/mL}$ are clinically relevant cutoff values and are largely considered in literature and guidelines. (22) Clinical cutoff values of “euthyroidism”, “hypothyroidism”, and “hyperthyroidism” depend on various factors and might vary across populations, laboratories, sex groups, during pregnancy, and across age spans. (23) For the sensitivity analysis, thyroid function was classified into three TSH ranges limited by 0.4 and 4.5 $\mu\text{IU/mL}$, which were considered relevant cutoff values for this study (“ $\text{TSH} < 0.4$ ”, “ $0.4 \leq \text{TSH} \leq 4.5$ ”, and “ $\text{TSH} > 4.5$ ”), without further dysthyroidism-related labeling.

2.3. Neuropsychological testing

Alzheimer's Disease Assessment Scale–13-item (ADAS_{13}) score was included as a valid tool to assess the overall cognitive status of the ADNI population. Moreover, the Mini-Mental

Examination total score (MMSE), Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB), Functional Activity Questionnaire total score (FAQ), and Geriatric Depression Score (GDS) – 15 items total score were added to the descriptive and correlation analyses.

2.4. Inclusion criteria

HC and MCI ADNI participants with complete TSH assessment $< 10 \mu\text{IU/mL}$, complete biometric/demographic (age, sex, educational background, height, and weight) data, complete GDS baseline assessment with GDS total score < 5 (to exclude cases with depression symptoms), (24) and complete ADAS₁₃ scores at baseline were eligible. A detailed flow chart is presented in Figure 1.




Figure 1: Flow chart of included cases

2.5. Statistical analysis

The study was based on a cross-sectional analysis of ADNI data at baseline. Median (IQR) and number (%) were reported according to the variable type (continuous and count, respectively). Wilcoxon rank sum test, Pearson's Chi-squared test, Kruskal-Wallis rank sum test, and Fisher's exact test were performed depending on the assessed variable and the

number of compared groups. The p -value was reported for each test. Data was stratified for (1) sex (male and female), and (2) main diagnosis (HC and MCI) as a biomarker of the neurodegenerative state.

Spearman correlation was used to study the association between continuous demographical and cognitive variables, and TSH values. A matrix including the correlation coefficients was visualized in the total population and each stratum.

Linear regression was performed to study the association between TSH levels and ADAS₁₃ scores in the total study population, first with a univariable model, then with a multivariable one; adjusted for age (years), sex (male/female), educational background (years of education), racial profile (“White”, “Black”, “Other”), APOE ϵ 4 status (no alleles, one allele, and two alleles), cognition-related main diagnosis (HC or MCI), and BMI (Weight(kg)/Height(m)²). ADAS₁₃ score was included as a dependent variable and continuous TSH levels (μ U/mL) as an independent variable.

After stratification, univariable linear regression was performed in each stratum. Then, the models were adjusted accordingly for confounding factors:

- **Sex stratum:** age, educational background, racial profile, APOE ϵ 4 status, cognition-related main diagnosis, and BMI.
- **Neurodegeneration-related stratum:** age, sex, educational background, racial profile, APOE ϵ 4 status, and BMI.

Results of linear regressions were reported as regression coefficient (β), 95% confidence interval (CI), and p -value.

A sensitivity analysis was performed based on TSH ranges as a categorical variable. TSH ranges were included in the linear regression models as independent variables, first in the main study population, and then in the different strata. Both crude and adjusted models, as

previously described, were evaluated. The middle TSH range was set as a reference and the regression coefficient β , 95% CI, and p -value in both groups of “TSH < 0.4” and “TSH > 4.5” were reported in relation to the reference group.

In a second step, a logistic regression analysis was performed to assess the association between thyroid function and the odds of being diagnosed with MCI at baseline. In the main analysis, MCI (binary: yes/no) as a dependent variable, and continuous TSH levels ($\mu\text{IU/mL}$) as an independent variable were included in the model. First, a crude model was assessed. Then, the same confounders (age, sex, educational background, racial profile, APOE $\epsilon 4$ status, and BMI) were added to the adjusted model. The analysis was repeated in sex strata adjusting accordingly for the confounders (age, educational background, racial profile, APOE $\epsilon 4$ status, and BMI). The sensitivity analysis followed the previously described steps, and TSH ranges were included as predictors in the models. In a further sensitivity analysis, restricted cubic splines were introduced to the model to assess non-linearity in the association. The resulting significant cutoff value was considered to reevaluate the TSH-MCI association, following the strategy of adjustment and stratification already described. The significance level for the null hypothesis was fixed at 0.05 (two-tailed).

Statistical analyses and data visualization were performed with RStudio (version 2024.04.1).

3. Results

3.1. Characteristics of study participants

A total of 1845 participants with a median age of 73 (IQR: 68, 78) met the inclusion criteria; 958 (52%) of whom were males, 887 were females (48%), 789 (42.76%) were HC, while 1056 (57.24%) had MCI. The median TSH level in the main population at baseline was 1.70 $\mu\text{IU/mL}$ (IQR: 1.15, 2.40), ranged from < 0.01 (three cases that were transformed to 0.01 for the

analysis) to 9.58 $\mu\text{IU/mL}$, and 58 (3.14%) participants had TSH levels < 0.4 , 48 (2.60%) TSH > 4.5 , and 1739 (94.25%) had TSH levels between 0.4 and 4.5 $\mu\text{IU/mL}$. The population characteristics and differences between groups are summarized in Table 1. Further TSH-specific analyses are visualized in Figure 2.




Figure 2: Comparative analyses between study participants and relevant associations. **2. A:** Kruskal-Wallis test of thyroid function and ADAS₁₃ score: Total study population. **2. B:** Kruskal-Wallis test of thyroid function and ADAS₁₃ score: Females. **2. C:** Kruskal-Wallis test of thyroid function and ADAS₁₃ score: Males. **2. D:** Mann-Whitney test of TSH levels in males and females. **2. E:** Mann-Whitney test of ADAS₁₃ scores in males and females. **2. F:** Linear regression between age (years) as predicting variable and TSH levels ($\mu\text{IU/mL}$) as outcome: Total study population, healthy controls, and Mild cognitive impairment

The median TSH value was significantly lower in the MCI group than in HC (1.66 vs. 1.74, p -value: 0.017). The CDR-SB and FAQ scores were higher in those with TSH < 0.4 $\mu\text{IU/mL}$ than the two other TSH range groups (1.00 vs. 0.5 and 0.0, p -value=0.030 and 1.00 vs. 0.0 and 0.0, p -value=0.005, respectively). No statistically significant differences were observed in the number of MCI cases across the TSH groups.

Table 1: Characteristics of the total study population and group comparison

Characteristic	Total study population		Main diagnosis			Thyroid function			p-value ³
	N	Overall N = 1845 ¹	Healthy controls N = 789 ¹	MCI N = 1056 ¹	p-value ²	TSH < 0.4 N = 58 ¹	0.4 ≤ TSH ≤ 4.5 N = 1739 ¹	TSH > 4.5 N = 48 ¹	
Age (years)	1845	73 (68, 78)	72 (68, 77)	73 (68, 78)	0.081	71 (67, 78)	73 (68, 78)	76 (70, 80)	0.072
Sex	1845				<0.001				0.002
Female		887 (48%)	443 (56%)	444 (42%)		41 (71%)	825 (47%)	21 (44%)	
Male		958 (52%)	346 (44%)	612 (58%)		17 (29%)	914 (53%)	27 (56%)	
Marital status	1845				<0.001				0.4
Currently married		1,362 (74%)	551 (70%)	811 (77%)		46 (79%)	1,278 (73%)	38 (79%)	
Currently not married or unknown		483 (26%)	238 (30%)	245 (23%)		12 (21%)	461 (27%)	10 (21%)	
Racial profile	1845				<0.001				0.016
White		1,613 (87%)	655 (83%)	958 (91%)		57 (98%)	1,512 (87%)	44 (92%)	
Black		148 (8.0%)	91 (12%)	57 (5.4%)		1 (1.7%)	147 (8.5%)	0 (0%)	
Other		84 (4.6%)	43 (5.4%)	41 (3.9%)		0 (0%)	80 (4.6%)	4 (8.3%)	
Educational level (years)	1845	16.00 (14.00, 18.00)	16.00 (15.00, 18.00)	16.00 (14.00, 18.00)	<0.001	16.00 (13.25, 18.00)	16.00 (14.00, 18.00)	16.50 (15.75, 18.00)	0.055
APOE ε4 status	1672				<0.001				>0.9
0 allele		977 (58%)	487 (70%)	490 (50%)		33 (59%)	916 (58%)	28 (62%)	
1 allele		565 (34%)	190 (27%)	375 (39%)		19 (34%)	532 (34%)	14 (31%)	
2 alleles		130 (7.8%)	22 (3.1%)	108 (11%)		4 (7.1%)	123 (7.8%)	3 (6.7%)	
Missing values		173	90	83		2	168	3	
ADAS₁₃ total score	1845	12 (8, 18)	8 (5, 12)	16 (11, 21)	<0.001	12 (7, 16)	12 (8, 18)	11 (7, 17)	0.7
MMSE total score	1845	29.00 (27.00, 30.00)	29.00 (29.00, 30.00)	28.00 (26.00, 29.00)	<0.001	29.00 (28.00, 29.00)	29.00 (27.00, 30.00)	29.00 (27.00, 30.00)	0.7
CDR-SB	1845	0.50 (0.00, 1.50)	0.00 (0.00, 0.00)	1.50 (1.00, 2.00)	<0.001	1.00 (0.00, 1.88)	0.50 (0.00, 1.50)	0.00 (0.00, 1.00)	0.030
FAQ total score	1831	0.0 (0.0, 2.0)	0.0 (0.0, 0.0)	1.0 (0.0, 5.0)	<0.001	1.0 (0.0, 2.8)	0.0 (0.0, 2.0)	0.0 (0.0, 0.0)	0.005
Missing values		14	5	9		0	14	0	
BMI	1845	26.5 (24.1, 29.5)	26.8 (24.1, 30.0)	26.3 (24.1, 29.2)	0.035	25.5 (23.2, 29.3)	26.5 (24.1, 29.5)	26.4 (24.7, 30.8)	0.3
TSH level (μIU/mL)	1845	1.70 (1.15, 2.40)	1.74 (1.19, 2.49)	1.66 (1.09, 2.36)	0.017	0.15 (0.06, 0.26)	1.71 (1.18, 2.36)	5.24 (4.80, 6.02)	<0.001
Cognition-related diagnosis									0.055
Healthy controls						18 (31%)	745 (43%)	26 (54%)	
MCI						40 (69%)	994 (57%)	22 (46%)	

¹ Median (IQR); n (%), ² Wilcoxon rank sum test; ³ Pearson's Chi-squared test; ³ Kruskal-Wallis rank sum test; ³ Pearson's Chi-squared test; Fisher's exact test

ADAS₁₃: Alzheimer's Disease Assessment Scale-13 Items, **APOE**: Apolipoprotein E, **BMI**: Body-Mass Index, **CDR-SB**: Clinical Dementia Rating-Sum of Boxes, **FAQ**: Functional Activities Questionnaire

MCI: Mild Cognitive Impairment, **MMSE**: Mini-Mental Status Examination, **TSH**: Thyroid Stimulating Hormone

The correlation analyses are summarized in Figure 3. Only in males, a weak ($r_{\text{Spearman}} = -0.09$) but statistically significant correlation ($p\text{-value}_{\text{Spearman}} = 0.003$) was observed between ADAS₁₃ total score and TSH levels.




Figure 3: Correlation analyses in the total study population and sex and neurodegeneration-related strata. **3. A:** Correlation matrix: Total study population. **3. B:** Correlation matrix: Females. **3. C:** Correlation matrix: Males. **3. D:** Correlation matrix: Healthy controls. **3. E:** Correlation matrix: Mild cognitive impairment. **3. F:** Spearman correlation between ADAS₁₃ total score and TSH level: Total study population. **3. G:** Spearman correlation between ADAS₁₃ total score and TSH level: Females. **3. H:** Spearman correlation between ADAS₁₃ total score and TSH level: Males. **3. I:** Spearman correlation between ADAS₁₃ total score and TSH level: Healthy controls. **3. J:** Spearman correlation between ADAS₁₃ total score and TSH level: Mild cognitive impairment.

3.2. Thyroid function and overall cognition

The linear regression analysis is detailed in Figure 4. No significant association between TSH levels ($\mu\text{IU/mL}$) and ADAS_{13} score (points) was found in the main population. In the sex stratum, significant associations were reported only in males, first in the crude model (crude β_{Males} : -0.65; 95% *CI*: -1.0, -0.26; *p*-value: 0.001), then after adjustment for confounding factors (adj. β_{Males} : -0.40; 95% *CI*: -0.74, -0.07; *p*-value: 0.019).

Based on TSH ranges, thyroid function was significantly associated with overall cognition only in HC but did not survive the multivariable analysis. Details of the sensitivity analysis are reported in Table 2.




Figure 4: Linear regression analysis of ADAS_{13} total score (points) as an outcome variable and TSH levels ($\mu\text{IU/mL}$) as a predicting variable in the total study population and sex and neurodegeneration-related strata. **4. A:** Linear regression between TSH levels and ADAS_{13} scores: Total study population. **4. B:** Linear regression between TSH levels and ADAS_{13} scores: Sex strata (“Females” and “Males”). **4. C:** Linear regression between TSH levels and ADAS_{13} scores: Neurodegeneration-related strata (“Healthy controls” and “Mild cognitive impairment”).

Table 2: Crude and adjusted models of linear regression between overall cognition (ADAS₁₃ total score) as an outcome and thyroid function (TSH ranges) as a predicting variable

Characteristic	Total study population		Females		Males		Healthy controls		MCI	
	Crude model N=1845	Adjusted model N=1672	Crude model N=887	Adjusted model N=789	Crude model N=958	Adjusted model N=883	Crude model N=789	Adjusted model N=699	Crude model N=1056	Adjusted model N=973
	β (95% CI)	p-value	β (95% CI)	p-value	β (95% CI)	p-value	β (95% CI)	p-value	β (95% CI)	p-value
Crude model										
Thyroid function		0.5		0.8		0.2		0.013		0.5
0.4 ≤ TSH ≤ 4.5	—		—		—		—		—	
TSH < 0.4	-0.86 (-2.7, 0.94)		-0.43 (-2.6, 1.8)		0.21 (-3.0, 3.4)		-3.0 (-5.1, -1.0)		-1.2 (-3.3, 0.97)	
TSH > 4.5	-0.78 (-2.8, 1.2)		0.77 (-2.3, 3.8)		-2.2 (-4.7, 0.36)		-0.26 (-2.0, 1.4)		0.44 (-2.4, 3.3)	
Adjusted model										
Thyroid function		0.12		0.3		0.2		0.076		0.5
0.4 ≤ TSH ≤ 4.5	—		—		—		—		—	
TSH < 0.4	-1.5 (-3.0, -0.07)		-1.4 (-3.1, 0.38)		-2.0 (-4.7, 0.77)		-2.2 (-4.2, -0.31)		-1.2 (-3.2, 0.83)	
TSH > 4.5	-0.27 (-1.9, 1.4)		0.66 (-1.8, 3.1)		-1.3 (-3.5, 0.90)		-0.15 (-1.8, 1.5)		-0.67 (-3.5, 2.1)	
Age (years)	0.19 (0.15, 0.23)	<0.001	0.21 (0.15, 0.27)	<0.001	0.17 (0.12, 0.23)	<0.001	0.17 (0.12, 0.22)	<0.001	0.19 (0.14, 0.25)	<0.001
BMI	-0.01 (-0.07, 0.04)	0.7	-0.02 (-0.09, 0.05)	0.6	0.01 (-0.09, 0.10)	0.9	0.08 (0.02, 0.14)	0.015	-0.09 (-0.18, -0.01)	0.033
Educational level	-0.34 (-0.44, -0.24)	<0.001	-0.28 (-0.43, -0.13)	<0.001	-0.38 (-0.52, -0.25)	<0.001	-0.21 (-0.33, -0.09)	<0.001	-0.43 (-0.57, -0.28)	<0.001
APOE ε4	1.5 (1.1, 2.0)	<0.001	2.0 (1.3, 2.6)	<0.001	1.2 (0.65, 1.8)	<0.001	0.02 (-0.54, 0.59)	>0.9	2.2 (1.6, 2.8)	<0.001
Racial profile		>0.9		0.3		0.4		0.2		0.6
White	—		—		—		—		—	
Black	0.00 (-1.2, 1.2)		0.39 (-1.1, 1.9)		-0.65 (-2.7, 1.4)		0.87 (-0.33, 2.1)		-0.81 (-2.9, 1.2)	
Other	-0.14 (-1.6, 1.3)		-1.5 (-3.5, 0.53)		1.3 (-0.74, 3.3)		-0.81 (-2.4, 0.80)		0.59 (-1.6, 2.7)	
Cog-Diagnosis		<0.001		<0.001		<0.001				
Healthy controls	—		—		—		—		—	
MCI	6.6 (6.1, 7.2)		7.4 (6.6, 8.2)		5.8 (5.1, 6.6)					
Sex		<0.001						<0.001		0.026
Female	—		—		—		—		—	
Male	1.5 (0.99, 2.1)						2.3 (1.7, 2.9)		0.94 (0.12, 1.8)	

ADAS₁₃: Alzheimer's Disease Assessment Scale – 13 items, APOE: Apolipoprotein E, BMI: Body-Mass Index, CI: Confidence Interval, Cog-Diagnosis: Cognition-related main diagnosis, MCI: Mild Cognitive Impairment, TSH: Thyroid Stimulating Hormone

3.3. Thyroid function and Mild Cognitive Impairment

The increase in TSH levels of one $\mu\text{U/mL}$ reduced 10% the odds of being diagnosed with MCI at baseline (crude OR_{Total} : 0.90; 95% *CI*: 0.83, 0.98; *p*-value: 0.013) in the total study population. The association remained statistically significant after adjusting for confounders (adj. OR_{Total} : 0.87; 95% *CI*: 0.79, 0.95; *p*-value: 0.002). After stratification, only in the male stratum, the increase of TSH levels predicted significantly lower odds of MCI at baseline (crude OR_{Males} : 0.82; 95% *CI*: 0.73, 0.93; *p*-value: 0.001), even after adjustment for confounding (adj. OR_{Males} : 0.80; 95% *CI*: 0.70, 0.92; *p*-value: 0.001) (Table 3). Sensitivity analysis based on TSH ranges showed similar results with $\text{TSH} < 0.4$ being associated with higher odds of MCI, while $\text{TSH} > 4.5$ with lower odds, compared to the intermediate range group (Table 4).

Table 3: Crude and adjusted models of logistic regression for the odds of MCI in the total study population, and in female and male strata – Continuous TSH levels ($\mu\text{IU/mL}$) as predicting variable

Characteristic	Total study population				Females				Males			
	N	Event N	OR (95% CI)	p-value	N	Event N	OR (95% CI)	p-value	N	Event N	OR (95% CI)	p-value
<u>Crude model</u>												
TSH level ($\mu\text{IU/mL}$)	1845	1056	0.90 (0.83, 0.98)	0.013	887	444	0.97 (0.86, 1.08)	0.555	958	612	0.82 (0.73, 0.93)	0.001
<u>Adjusted model</u>												
TSH level ($\mu\text{IU/mL}$)	1672	973	0.87 (0.79, 0.95)	0.002	789	401	0.94 (0.82, 1.06)	0.292	883	572	0.80 (0.70, 0.92)	0.001
Age (years)	1672	973	1.00 (0.98, 1.01)	0.536	789	401	1.00 (0.98, 1.02)	0.707	883	572	0.99 (0.97, 1.02)	0.561
BMI	1672	973	1.0 (0.97, 1.02)	0.629	789	401	1.00 (0.97, 1.03)	0.990	883	572	0.99 (0.95, 1.02)	0.469
APOE $\epsilon 4$	1672	973	2.07 (1.74, 2.48)	<0.001	789	401	1.98 (1.56, 2.53)	<0.001	883	572	2.19 (1.71, 2.85)	<0.001
Educational level	1672	973	0.90 (0.87, 0.94)	<0.001	789	401	0.91 (0.86, 0.97)	0.001	883	572	0.89 (0.85, 0.95)	<0.001
Racial profile	1672	973		0.024	789	401		0.073	883	572		0.319
White			—				—				—	
Black			0.53 (0.33, 0.84)				0.51 (0.28, 0.91)				0.57 (0.27, 1.27)	
Other			1.08 (0.62, 1.88)				0.90 (0.41, 1.97)				1.25 (0.58, 2.90)	
Sex	1672	973		<0.001								
Female			—									
Male			2.00 (1.62, 2.47)									

APOE: Apolipoprotein E, BMI: Body Mass Index, CI: Confidence Interval, OR: Odds Ratio, TSH: Thyroid Stimulating Hormone

Table 4: Crude and adjusted models of logistic regression for the odds of MCI in the total study population and in female and male strata – Thyroid function (TSH ranges) as predicting variable

Characteristic	Total study population				Females				Males			
	N	Event N	OR (95% CI)	p-value	N	Event N	OR (95% CI)	p-value	N	Event N	OR (95% CI)	p-value
<u>Crude model</u>												
Thyroid function	1845	1056		0.053	887	444		0.350	958	612		0.009
0.4 ≤ TSH ≤ 4.5			—				—				—	
TSH < 0.4			1.67 (0.96, 3.00)				1.59 (0.84, 3.08)				4.22 (1.18, 26.9)	
TSH > 4.5			0.63 (0.35, 1.13)				0.92 (0.38, 2.22)				0.45 (0.20, 0.97)	
<u>Adjusted model</u>												
Thyroid function	1672	973		0.018	789	401		0.402	883	572		0.011
0.4 ≤ TSH ≤ 4.5			—				—				—	
TSH < 0.4			1.87 (1.04, 3.49)				1.55 (0.79, 3.12)				3.88 (1.05, 25.1)	
TSH > 4.5			0.55 (0.29, 1.04)				0.84 (0.32, 2.11)				0.40 (0.17, 0.92)	
Age (years)	1672	973	1.00 (0.98, 1.01)	0.512	789	401	1.00 (0.98, 1.02)	0.709	883	572	0.99 (0.97, 1.01)	0.516
BMI	1672	973	1.0 (0.97, 1.02)	0.641	789	401	1.00 (0.97, 1.03)	0.998	883	572	0.99 (0.95, 1.02)	0.496
APOE ε4	1672	973	2.09 (1.76, 2.49)	<0.001	789	401	1.99 (1.56, 2.54)	<0.001	883	572	2.23 (1.73, 2.89)	<0.001
Educational level	1672	973	0.90 (0.87, 0.94)	<0.001	789	401	0.91 (0.86, 0.97)	0.002	883	572	0.89 (0.85, 0.95)	<0.001
Racial profile	1672	973		0.048	789	401		0.103	883	572		0.340
White			—				—				—	
Black			0.57 (0.35, 0.90)				0.53 (0.29, 0.95)				0.61 (0.28, 1.35)	
Other			1.11 (0.64, 1.93)				0.91 (0.42, 1.98)				1.37 (0.63, 3.17)	
Sex	1672	973		<0.001								
Female			—				—				—	
Male			2.04 (1.65, 2.52)									

APOE: Apolipoprotein E, BMI: Body-Mass Index, CI: Confidence Interval, OR: Odds Ratio, TSH: Thyroid Stimulating Hormone

The introduction of a non-linear factor to the model using the restricted cubic splines, showed that the median TSH value (1.70 $\mu\text{U/mL}$) was a significant cutoff value for the association in the total study population and males, but not females (Figure 5). Prediction analysis based on the TSH cutoff value showed that the odds of MCI were significantly higher in people with TSH < 1.70 $\mu\text{U/mL}$ than in those with TSH levels beyond this cutoff value. The association was significant in the total study population after adjustment for confounders and males, but not females (Table 5). Predicted odds ratios in each stratum in the main and sensitivity analyses are summarized in Figure 6.




Figure 5: Splines of predicted odds ratios in the total study population and sex strata. **5. A:** TSH variation and predicted odds ratios of MCI: Total study population. **5. B:** TSH variation and predicted odds ratios of MCI: Females. **5. C:** TSH variation and predicted odds ratios of MCI: Males.

Table 5: Crude and adjusted models of logistic regression for the odds of MCI in the total study population and female and male strata – The TSH groups based on a median value as predicting variable

Characteristic	Total study population				Females				Males			
	N	Event N	OR (95% CI)	p-value	N	Event N	OR (95% CI)	p-value	N	Event N	OR (95% CI)	p-value
Crude model												
TSH–median reference	1845	1056		0.147	887	444		0.815	958	612		0.055
TSH > 1.70			—				—				—	
TSH ≤ 1.70			1.15 (0.95, 1.38)				1.03 (0.79, 1.34)				1.30 (1.00, 1.69)	
Adjusted model												
TSH–median reference	1672	973		0.027	789	401		0.442	883	572		0.019
TSH > 1.70			—				—				—	
TSH ≤ 1.70			1.26 (1.03, 1.54)				1.12 (0.84, 1.50)				1.41 (1.06, 1.89)	
Age (years)	1672	973	1.0 (0.98, 1.01)	0.488	789	401	1.00 (0.97, 1.02)	0.667	883	572	0.99 (0.97, 1.02)	0.566
BMI	1672	973	1.0 (0.97, 1.02)	0.644	789	401	1.00 (0.97, 1.03)	0.998	883	572	0.99 (0.95, 1.02)	0.481
APOE ε4	1672	973	2.08 (1.75, 2.48)	<0.001	789	401	1.98 (1.56, 2.53)	<0.001	883	572	2.20 (1.71, 2.85)	<0.001
Educational level	1672	973	0.90 (0.87, 0.94)	<0.001	789	401	0.91 (0.86, 0.97)	0.001	883	572	0.89 (0.84, 0.94)	<0.001
Racial profile	1672	973		0.032	789	401		0.080	883	572		0.354
White			—				—				—	
Black			0.54 (0.34, 0.86)				0.52 (0.28, 0.92)				0.59 (0.27, 1.31)	
Other			1.07 (0.62, 1.86)				0.89 (0.41, 1.95)				1.26 (0.58, 2.90)	
Sex	1672	973		<0.001								
Female			—				—				—	
Male			1.99 (1.61, 2.46)									

APOE: Apolipoprotein E, BMI: Body-Mass Index, CI: Confidence Interval, OR: Odds Ratio, TSH: Thyroid Stimulating Hormone




Figure 6: Summary plots of predicted odds ratios in the total study population and sex strata

4. Discussion

The high number of study participants, the exclusion of dementia, overt hypothyroidism, and depression as relevant confounders, and the sex stratification were major strengths of this study. The first outcome was the significant association between TSH levels and ADAS₁₃ scores. Although no statistically significant results have been found in the main study population, significant associations between thyroid function and overall cognition were revealed in male participants after stratifying for sex. The second outcome was the value of TSH in significantly predicting MCI diagnosis at baseline, particularly in elderly males. The association between TSH and MCI diagnosis was particularly significant in those with TSH levels lower than the median TSH value (1.70 µIU/mL).

4.1. Thyroid function and cognition

The association between TSH levels and cognition in the elderly was controversial in the literature. While some studies on older euthyroid adults did not identify significant associations between TSH and free T4 (FT4, thyroxine) levels and cognition, (25) other studies reported significant associations between lower thyroid hormones – free T3 (FT3, tri-iodothyronine) and cognitive impairment. (26)

In studies where both euthyroid patients as well as patients with subclinical hypo- and hyperthyroidism were included, no significant association was found between thyroid hormones and MMSE scores, despite the higher age of included patients (85 years). (27) TSH did not show a significant association with CERAD subdomains in patients of 75 years and older, but higher TSH levels were significantly correlated with better CDR scores than lower levels. (28)

While those studies focused on associations between thyroid function and cognitive tests, a further prospective cohort did not show a significant value of TSH in predicting the progression from MCI to dementia within three years in euthyroid and hypothyroid elderly patients. (29) In contrast, lower TSH levels at baseline predicted progression to MCI or dementia over five years in Korean euthyroid and at baseline non-demented elderly. (30)

The sample size and inclusion criteria seem to affect the reported results and explain the controversies in published data. The current study was based on estimating the overall cognition using ADAS₁₃ scores, but the outcome of published data was sometimes based on continuous scores (MMSE, CERAD), or binary outcomes such as conversion to MCI or dementia, and particular interest was given to exploring the associations in higher TSH levels or hypothyroidism.

TSH levels tend to increase with age, and physiological ranges have to be adapted accordingly. Subclinical hypothyroidism is a more common condition in the elderly and does not necessarily implicate a pathological status or necessitate hormone therapy. (17, 18) In the current study, higher age was associated with higher TSH levels in the total study population and after stratification in healthy controls but not in participants with MCI. In a placebo-controlled randomized clinical trial, hormonal supplementation in older adults with subclinical hypothyroidism did not show a significant impact on cognitive function. (31) In older populations (85 years), a longitudinal decrease in TSH levels was associated with a concomitant reduction in MMSE scores over a three- and five-year follow-up period. (32) Thyrotoxicosis is a rarer condition in which patients present very high thyroid hormones either of endogenous or exogenous etiology (corresponding to very low TSH). In a study including 65931 elderly patients aged 65 years and older, thyrotoxicosis was associated with a significantly higher risk of cognitive decline. (33) Among the included cases from the ADNI cohort, three participants had TSH levels of < 0.01 and were converted to 0.01 for the analysis. Despite that, the present study confirmed that lower TSH levels (independently from thyrotoxicosis) were associated with worse cognitive scores and a higher risk of being diagnosed with MCI. These results were particularly significant under a cutoff value corresponding to the median TSH value in males, but not females.

4.2. Effect of sex on the relationship between thyroid function and cognition

Samuels and colleagues studied in a cross-sectional and longitudinal design eventual associations between the variation of thyroid function within age-adapted normal ranges, and cognition in older men (≥ 65 years). Neither TSH nor FT_4 showed statistically significant results. (34) This contradicts another study in elderly men aged between 70 and 89 years,

where higher FT₄ (but not TSH) levels were associated with higher dementia incidence. (35)

In women between 30 and 64 years old, higher TSH levels were significantly associated with a faster decline in clock-command scores. (36) Moreover, in a cross-sectional analysis of 2563 euthyroid elderly aged between 50 and 80 years, higher TSH levels were significantly associated with the diagnosis of MCI only in women. (37)

The paradoxical association between thyroid function and cognition seen in male (negative association) and female (positive association) strata was an interesting outcome in the current study. However, the statistical significance of the analysis was only observed in elderly males. The present findings confirm previous studies in favor of a sex-dependent association between thyroid hormones and cognition in the elderly. (38) Yet, eventual sex-specific confounding factors need to be better understood.

4.3. Effect of age on the relationship between thyroid function and cognition

Thyroid function affects the elderly differently across ages. While studies in the elderly reported controversial results, a large cross-sectional analysis including 10362 middle-aged adults (mean: 49.5 ±7.4 years) showed that lower TSH levels are associated with impaired executive function. (39) Moreover, higher TSH levels were associated with poorer cognition in adults under 59 years and better performance in those older than 60 years. (40)

4.4. Effect of neurodegeneration on thyroid-cognition relationship

Although neither elderly with dementia nor TSH measurements in cerebrospinal fluid were included in the current analysis, studies have reported a biological association between thyroid hormones and Alzheimer's pathology, even within euthyroid elderly. (41-43) While stratifying for the biomarker of the neurodegenerative status (HC vs. MCI) did not show

significant associations between thyroid function and cognition after adjusting for confounding factors, the association between TSH and Alzheimer's disease biological biomarkers was out of the scope of this study. Further investigations are needed, particularly to assess whether sex impacts similarly this association.

4.5. Limitations

The first limitation of our study is related to the lower number of participants with thyroid levels beyond cutoff values compared to participants with relatively "normal" TSH levels at baseline. This might be related to the healthcare awareness and compliance in persons with health-seeking behavior, who are more likely to consent to be study participants in a longitudinal cohort like ADNI. Moreover, people with severe comorbidities were not eligible for the study. Furthermore, the study was only based on TSH levels without evaluating the potential effect of peripheral thyroid hormones (FT₃ and FT₄). This is mainly due to the lack of additional laboratory data in the accessible ADNI database.

The second limitation is the non-inclusion of the medical history related to thyroid pathologies, particularly whether there was an underlying supplemented hypothyroidism or an eventual history of thyroid (surgery/radioiodine) ablation. Moreover, information on potential concomitant autoimmune diseases such as Graves or Hashimoto thyroiditis was out of the scope of the study. This is primarily due to the coding system's reliability, based on self-reporting of medical history. This might consequently lead to higher risks of recall or assessment bias. The main exposure of the study was the central thyroid function based on TSH levels independently from etiologies and endocrine comorbidities.

Larger population-based longitudinal studies are needed to infer a potential causal effect and assess the associations in risk groups, particularly to better understand the role of sex in modulating the observed effects.

4.6. Perspectives and significance

This study highlighted the importance of sex in modulating the association between thyroid function and cognition. Low TSH levels are associated with higher odds of being diagnosed with MCI, and this association might be revealed only after stratifying for sex and exploring separately males and females. TSH-related cognitive impairment is largely believed to be a reversible condition, especially when associated with overt hypothyroidism. Thus, the reversibility of cognitive decline associated with lower TSH levels has to be tested in further randomized studies. It is also important to replicate the findings in different populations and test for non-linearity. The predictive value and the biological significance of the median TSH level in older males need to be more studied and better understood. The sex-dependent neurobiology of cognition in the context of thyroid function needs to be further explored to decrypt the paradoxical differences between males and females.

5. Conclusions

This study provides additional arguments supporting the theory of a multifaceted brain-thyroid interaction in advanced ages. Sex infers significantly the association between thyroid function and cognition in older populations, and the association is subject to a cutoff value. Lower TSH values were associated with cognitive decline in elderly males but not females, but the underlying mechanisms need to motivate further research.

Declarations

Ethics approval and consent to participate: Ethical approvals were obtained from corresponding IRBs in each recruitment site. Written consent was obtained from every ADNI study participant. More information is available at <http://adni.loni.usc.edu>

Consent for publication: Not applicable. Brain and Thyroid vectors used in the graphical abstract are designed by Freepik (License free).

Availability of data and materials: The datasets supporting the conclusions of this article are available at <http://adni.loni.usc.edu>

Competing interest: None.

Funding: AH did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector.

Data collection and sharing for the ADNI project was funded by the National Institutes of Health (Grant U19 AG024904). ADNI is made possible with funding from the NIH and private sector support detailed at <https://adni.loni.usc.edu/about/>.

Author's contributions: AH has full access to all of the data and takes responsibility for the integrity of the data and the accuracy of the analysis, visualization, drafting, and editing of the manuscript.

*Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI

investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Acknowledgments: “Data collection and sharing for the Alzheimer's Disease Neuroimaging Initiative (ADNI) is funded by the National Institute on Aging (National Institutes of Health Grant U19 AG024904). The grantee organization is the Northern California Institute for Research and Education. In the past, ADNI has also received funding from the National Institute of Biomedical Imaging and Bioengineering, the Canadian Institutes of Health Research, and private sector contributions through the Foundation for the National Institutes of Health (FNIH) including generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics.”

References

1. Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *The Lancet Public Health*. 2022;7(2):e105-e25.

2. Liu YY, Brent GA. The Role of Thyroid Hormone in Neuronal Protection. *Compr Physiol*. 2021;11(3):2075-95.
3. Lain SJ, Bentley JP, Wiley V, Roberts CL, Jack M, Wilcken B, et al. Association between borderline neonatal thyroid-stimulating hormone concentrations and educational and developmental outcomes: a population-based record-linkage study. *Lancet Diabetes Endocrinol*. 2016;4(9):756-65.
4. Korevaar TI, Muetzel R, Medici M, Chaker L, Jaddoe VW, de Rijke YB, et al. Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. *Lancet Diabetes Endocrinol*. 2016;4(1):35-43.
5. Baksi S, Pradhan A. Thyroid hormone: sex-dependent role in nervous system regulation and disease. *Biol Sex Differ*. 2021;12(1):25.
6. Freuer D, Meisinger C. Causal link between thyroid function and schizophrenia: a two-sample Mendelian randomization study. *Eur J Epidemiol*. 2023;38(10):1081-8.
7. Chen G, Lv H, Zhang X, Gao Y, Liu X, Gu C, et al. Assessment of the relationships between genetic determinants of thyroid functions and bipolar disorder: A mendelian randomization study. *J Affect Disord*. 2022;298(Pt A):373-80.
8. Barbero JD, Gutiérrez-Zotes A, Montalvo I, Creus M, Cabezas Á, Solé M, et al. Free thyroxine levels are associated with cognitive abilities in subjects with early psychosis. *Schizophr Res*. 2015;166(1-3):37-42.
9. Labad J, Barbero JD, Gutiérrez-Zotes A, Montalvo I, Creus M, Cabezas Á, et al. Free thyroxine levels are associated with cognitive changes in individuals with a first episode of psychosis: A prospective 1-year follow-up study. *Schizophr Res*. 2016;171(1-3):182-6.

10. Saglam Y, Ermis C, Tanyolac D, Oz A, Turan S, Korkmaz HA, et al. The association between plasma thyroxine levels and neurocognitive impairment in early-onset schizophrenia and other psychosis spectrum disorders. *Prog Neuropsychopharmacol Biol Psychiatry*. 2024;131:110940.
11. Lai S, Zhong S, Zhang Y, Wang Y, Zhao H, Chen G, et al. Association of altered thyroid hormones and neurometabolism to cognitive dysfunction in unmedicated bipolar II depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2021;105:110027.
12. Pasqualetti G, Pagano G, Rengo G, Ferrara N, Monzani F. Subclinical Hypothyroidism and Cognitive Impairment: Systematic Review and Meta-Analysis. *J Clin Endocrinol Metab*. 2015;100(11):4240-8.
13. Ge YJ, Xu W, Tan CC, Tan L. Blood-based biomarkers in hypothalamic-pituitary axes for the risk of dementia or cognitive decline: a systematic review and meta-analysis. *Aging (Albany NY)*. 2020;12(20):20350-65.
14. Gan EH, Pearce SH. Clinical review: The thyroid in mind: cognitive function and low thyrotropin in older people. *J Clin Endocrinol Metab*. 2012;97(10):3438-49.
15. Akintola AA, Jansen SW, van Bodegom D, van der Grond J, Westendorp RG, de Craen AJ, et al. Subclinical hypothyroidism and cognitive function in people over 60 years: a systematic review and meta-analysis. *Front Aging Neurosci*. 2015;7:150.
16. van Vliet NA, van Heemst D, Almeida OP, Åsvold BO, Aubert CE, Bae JB, et al. Association of Thyroid Dysfunction With Cognitive Function: An Individual Participant Data Analysis. *JAMA Intern Med*. 2021;181(11):1440-50.
17. Biondi B, Cappola AR, Cooper DS. Subclinical Hypothyroidism: A Review. *Jama*. 2019;322(2):153-60.

18. Biondi B, Cappola AR. Subclinical hypothyroidism in older individuals. *Lancet Diabetes Endocrinol.* 2022;10(2):129-41.
19. Vanderpump MPJ. Epidemiology of Thyroid Disorders. In: Luster M, Duntas LH, Wartofsky L, editors. *The Thyroid and Its Diseases: A Comprehensive Guide for the Clinician.* Cham: Springer International Publishing; 2019. p. 75-85.
20. Jockwitz C, Wiersch L, Stumme J, Caspers S. Cognitive profiles in older males and females. *Scientific Reports.* 2021;11(1):6524.
21. Sohn D, Shpanskaya K, Lucas JE, Petrella JR, Saykin AJ, Tanzi RE, et al. Sex Differences in Cognitive Decline in Subjects with High Likelihood of Mild Cognitive Impairment due to Alzheimer's disease. *Scientific Reports.* 2018;8(1):7490.
22. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JL, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. *Thyroid.* 2012;22(12):1200-35.
23. Xing D, Liu D, Li R, Zhou Q, Xu J. Factors influencing the reference interval of thyroid-stimulating hormone in healthy adults: A systematic review and meta-analysis. *Clinical Endocrinology.* 2021;95(3):378-89.
24. Pocklington C, Gilbody S, Manea L, McMillan D. The diagnostic accuracy of brief versions of the Geriatric Depression Scale: a systematic review and meta-analysis. *International Journal of Geriatric Psychiatry.* 2016;31(8):837-57.
25. Booth T, Deary IJ, Starr JM. Thyroid stimulating hormone, free thyroxine and cognitive ability in old age: the Lothian Birth Cohort Study 1936. *Psychoneuroendocrinology.* 2013;38(4):597-601.

26. Chen H, Hu J, Yang X, Zhou Q, Hu Y, Tang X, et al. Low levels of free triiodothyronine are associated with risk of cognitive impairment in older euthyroid adults. *Sci Rep.* 2023;13(1):22133.
27. Formiga F, Ferrer A, Padros G, Contra A, Corbella X, Pujol R. Thyroid status and functional and cognitive status at baseline and survival after 3 years of follow-up: the OCTABAIX study. *Eur J Endocrinol.* 2014;170(1):69-75.
28. Ojala AK, Schalin-Jääntti C, Pitkälä KH, Tilvis RS, Strandberg TE. Serum thyroid-stimulating hormone and cognition in older people. *Age Ageing.* 2016;45(1):155-7.
29. Pyun JM, Park YH, Kim S. Subclinical Hypothyroidism and Cognitive Impairment. *J Alzheimers Dis.* 2022;88(2):757-62.
30. Moon JH, Park YJ, Kim TH, Han JW, Choi SH, Lim S, et al. Lower-but-normal serum TSH level is associated with the development or progression of cognitive impairment in elderly: Korean Longitudinal Study on Health and Aging (KLoSHA). *J Clin Endocrinol Metab.* 2014;99(2):424-32.
31. Parle J, Roberts L, Wilson S, Pattison H, Roalfe A, Haque MS, et al. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. *J Clin Endocrinol Metab.* 2010;95(8):3623-32.
32. Gan EH, Jagger C, Yadegarfar ME, Duncan R, Pearce SH. Changes in Serum Thyroid Function Predict Cognitive Decline in the Very Old: Longitudinal Findings from the Newcastle 85+ Study. *Thyroid.* 2021;31(8):1182-91.
33. Adams R, Oh ES, Yasar S, Lyketsos CG, Mammen JS. Endogenous and Exogenous Thyrotoxicosis and Risk of Incident Cognitive Disorders in Older Adults. *JAMA Intern Med.* 2023;183(12):1324-31.

34. Samuels MH, Kaimal R, Waring A, Fink HA, Yaffe K, Hoffman AR, et al. Thyroid Function Variations Within the Reference Range Do Not Affect Quality of Life, Mood, or Cognitive Function in Community-Dwelling Older Men. *Thyroid*. 2016;26(9):1185-94.
35. Yeap BB, Alfonso H, Chubb SA, Puri G, Hankey GJ, Flicker L, et al. Higher free thyroxine levels predict increased incidence of dementia in older men: the Health in Men Study. *J Clin Endocrinol Metab*. 2012;97(12):E2230-7.
36. Beydoun MA, Beydoun HA, Rostant OS, Dore GA, Fanelli-Kuczmariski MT, Evans MK, et al. Thyroid hormones are associated with longitudinal cognitive change in an urban adult population. *Neurobiol Aging*. 2015;36(11):3056-66.
37. Winkler A, Weimar C, Jöckel KH, Erbel R, Dragano N, Broecker-Preuss M, et al. Thyroid-Stimulating Hormone and Mild Cognitive Impairment: Results of the Heinz Nixdorf Recall Study. *J Alzheimers Dis*. 2016;49(3):797-807.
38. Beydoun MA, Beydoun HA, Kitner-Triolo MH, Kaufman JS, Evans MK, Zonderman AB. Thyroid hormones are associated with cognitive function: moderation by sex, race, and depressive symptoms. *J Clin Endocrinol Metab*. 2013;98(8):3470-81.
39. Szejf C, Suemoto CK, Santos IS, Lotufo PA, Haueisen Sander Diniz MF, Barreto SM, et al. Thyrotropin level and cognitive performance: Baseline results from the ELSA-Brasil Study. *Psychoneuroendocrinology*. 2018;87:152-8.
40. Beydoun MA, Beydoun HA, Shroff MR, Kitner-Triolo MH, Zonderman AB. Serum leptin, thyroxine and thyroid-stimulating hormone levels interact to affect cognitive function among US adults: evidence from a large representative survey. *Neurobiol Aging*. 2012;33(8):1730-43.

41. Ge F, Dong L, Zhu D, Lin X, Shi J, Xiao M. Comparison of Serum Triiodothyronine with Biomarkers for Alzheimer's Disease Continuum in Euthyroid Subjects. *J Alzheimers Dis.* 2022;85(2):605-14.
42. Choi BW, Kim S, Kang S, Won KS, Yi HA, Kim HW. Relationship Between Thyroid Hormone Levels and the Pathology of Alzheimer's Disease in Euthyroid Subjects. *Thyroid.* 2020;30(11):1547-55.
43. Johansson P, Almqvist EG, Johansson JO, Mattsson N, Hansson O, Wallin A, et al. Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. *Psychoneuroendocrinology.* 2013;38(7):1058-66.

Captions

- **Tables**

Table 1: Characteristics of the total study population and group comparison

Table 2: Crude and adjusted models of linear regression between overall cognition (ADAS₁₃ total score) as an outcome and thyroid function (TSH ranges) as a predicting variable

Table 3: Crude and adjusted models of logistic regression for the odds of MCI in the total study population, and in female and male strata – Continuous TSH levels (μ IU/mL) as predicting variable

Table 4: Crude and adjusted models of logistic regression for the odds of MCI in the total study population and in female and male strata – Thyroid function (TSH ranges) as predicting variable

Table 5: Crude and adjusted models of logistic regression for the odds of MCI in the total study population and female and male strata – The TSH groups based on a median value as predicting variable

- **Figures**

Figure 1: Flow chart of included cases

Figure 2: Comparative analyses between study participants and relevant associations

Figure 2. A: Kruskal-Wallis test of thyroid function and ADAS₁₃ score: Total study population

Figure 2. B: Kruskal-Wallis test of thyroid function and ADAS₁₃ score: Females

Figure 2. C: Kruskal-Wallis test of thyroid function and ADAS₁₃ score: Males

Figure 2. D: Mann-Whitney test of TSH levels in males and females

Figure 2. E: Mann-Whitney test of ADAS₁₃ scores in males and females

Figure 2. F: Linear regression between age (years) as predicting variable and TSH levels ($\mu\text{IU/mL}$) as outcome: Total study population, healthy controls, and Mild cognitive impairment

Figure 3: Correlation analyses in the total study population and sex and neurodegeneration-related strata

Figure 3. A: Correlation matrix: Total study population

Figure 3. B: Correlation matrix: Females

Figure 3. C: Correlation matrix: Males

Figure 3. D: Correlation matrix: Healthy controls

Figure 3. E: Correlation matrix: Mild cognitive impairment

Figure 3. F: Spearman correlation between ADAS₁₃ total score and TSH level: Total study population

Figure 3. G: Spearman correlation between ADAS₁₃ total score and TSH level: Females

Figure 3. H: Spearman correlation between ADAS₁₃ total score and TSH level: Males

Figure 3. I: Spearman correlation between ADAS₁₃ total score and TSH level: Healthy controls

Figure 3. J: Spearman correlation between ADAS₁₃ total score and TSH level: Mild cognitive impairment

Figure 4: Linear regression analysis of ADAS₁₃ total score (points) as an outcome variable and TSH levels ($\mu\text{IU/mL}$) as a predicting variable in the total study population and sex and neurodegeneration-related strata

Figure 4. A: Linear regression between TSH levels and ADAS₁₃ scores: Total study population

Figure 4. B: Linear regression between TSH levels and ADAS₁₃ scores: Sex strata (“Females” and “Males”)

Figure 4. C: Linear regression between TSH levels and ADAS₁₃ scores: Neurodegeneration-related strata (“Healthy controls” and “Mild cognitive impairment”)

Figure 5: Splines of predicted odds ratios in the total study population and sex strata

Figure 5. A: TSH variation and predicted odds ratios of MCI: Total study population

Figure 5. B: TSH variation and predicted odds ratios of MCI: Females

Figure 5. C: TSH variation and predicted odds ratios of MCI: Males

Figure 6: Summary plots of predicted odds ratios in the total study population and sex strata